Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rande Is. . .FISHING. . [under $1.50] -- Ignore unavailable to you. Want to Upgrade?

To: Chartgod who wrote (3351)	12/19/2000 9:22:41 AM
From: Rande Is	Read Replies (1) \| Respond to of 4766

Integrated Surgical Systems Announces First Successful DigiMatch (Pinless) HipSurgery in the USA DAVIS, Calif., Dec. 19 /PRNewswire/ -- Integrated Surgical Systems, Inc. (ISS) (Nasdaq: RDOC), a pioneer in medical robotics and the world leader in image-directed, semi-autonomous robotic products for surgical applications, announced that the first successful DigiMatch (Pinless) Total Hip Replacement (THR) surgery with its ROBODOC(R) Surgical Assistant System (ROBODOC) was performed today. (Photo: newscom.com ) The surgery was performed by William Bargar M.D. at Sutter General Hospital in Sacramento, California. "Based on my experience as the principal investigator in the clinical studies for the pinbased system, this new DigiMatch (Pinless) Procedure appears to be simple but equally accurate. Not having to use the pins as the fiduciary markers allows us to eliminate the need for a separate surgery to place the pins and reduces the overall surgical time," commented Dr. Bargar. Professor Dr. Borner, the Medical Director of BGU Clinical in Frankfurt, Germany, was present during the surgery and provided clinical support in the landmark Pinless THR surgery. Prof. Dr. Borner has performed over 3,000 ROBODOC hip and knee surgeries since 1994 and he is known worldwide as the leader for robotic joint replacement surgeries. Dr. Ramesh C. Trivedi, President & CEO of Integrated Surgical Systems added, "We are delighted to finally start the clinical trials for the DigiMatch (Pinless) ROBODOC System in the USA. It has been in routine use in Europe since September of 1998. There both the patients and surgeons prefer this pinless technology since it does away with any pre-operative surgery to place the pins and patients recover sooner. It also eliminates the occasional post operative knee pain experienced by the patient. In addition, it reduces the cost of the entire procedure." The other two sites are scheduled to join Sutter Medical Center in clinical trials in the next few weeks. All the sites will use the VerSys line of cementless hip prosthesis made by Zimmer, Inc. a subsidiary of Bristol-Myers Squibb (NYSE: BMY). The clinical study, requiring a total of 160 patients is expected to take five months to complete. Following the multicenter clinical trials, U.S. surgeons and Integrated Surgical Systems expect to obtain FDA approval by the end of 2001. The Products: ROBODOC is the robotic surgery system of ISS that is used for total joint arthoplasties. ROBODOC consists of a robotic arm assembly and a PC-based 3-D planning station called ORTHODOC(R). ISS has installed 37 ROBODOC systems worldwide. The ISS neurosurgery product, NeuroMate(TM), is the first robotic technology based system for use in stereotactic brain surgery. NeuroMate consists of a robotic arm assembly and a PC-based planning system. NeuroMate also interfaces with other popular planning stations offered by third-party vendors. ISS has installed 16 NeuroMate systems in the U.S., Europe, and Japan. The Company: Integrated Surgical Systems, Inc. develops, manufactures, markets and services computer-controlled, image-directed robotic products for surgical applications. ISS produces the ROBODOC Surgical Assistant System (ROBODOC), which is designed for orthopedic applications. The ROBODOC System has been used to perform successful total hip replacement surgeries on more than 7,300 patients worldwide. ROBODOC is currently being marketed in Europe and the Middle East. NeuroMate(TM), an ISS neurosurgery product, is the first robotic technology for use in stereotactic brain surgery and it has supported to date over 3,000 neurosurgical procedures. Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including the timely development and market acceptance of new products and upgrades to existing products, the impact of competitive products and pricing, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission (SEC). NOTE: ROBODOC(R) is a registered trademark of Integrated Surgical Systems, Inc. NeuroMate(TM) is a trademark of Integrated Surgical Systems, S.A.

To: Chartgod who wrote (3351)	12/21/2000 5:13:47 PM
From: sepku	Respond to of 4766

>even tho you hold it< yeah! that's not too good an endorsement is it....8-} but it still should be ( homer S. "please,please,please, please, please,please,please ) a good long term play. happy holidays

To: Chartgod who wrote (3351)	3/29/2001 10:48:25 AM
From: sepku	Read Replies (1) \| Respond to of 4766

JC...ONTR info.... found this on the RB board... ONTRO's Market Capitalization A rough estimate of the future market capitalization of ONTRO can be calculated using information that is readily available on the web. ONTRO's business model is based on collecting a royalty fee for each self-heating container that is sold. As a result, the future market capitalization of ONTRO can be estimated in terms of the number of self-heating containers that it expects to sell (NUMBER), the average price per container (PRICE), the royalty fee per container (ROYALTY), the after tax income (TAX), and the expected price earnings ratio (P/E): ONTRO's Market Capitalization = NUMBER x PRICE x ROYALTY x TAX x P/E First, let's provide estimates of ONTRO's market capitalization during the first year of sales and after three to five years of sales of self-heating containers. Then we will discuss the assumptions and research that have been used to derive the estimates. Consolidated Container Company estimates sales of 120M containers in the first year and 480M containers in 3 to 5 years (see Reference 2). I assume that the average price is $2.00 per container and the royalty fee is 5% of retail sales. If the after tax income is 60% and the P/E ratio is 40, then the market capitalizations of ONTRO in the first year and in 3 to 5 years are ONTRO's Market Cap. (first year) = 120M x $2.00 x 0.05 x 0.60 x 40 = $288M ONTRO's Market Cap. (3-5 years) = 480M x $2.00 x 0.05 x 0.60 x 40 = $1,152M Based on ONTRO's current market capitalization of $10M, there is a significant potential for growth. After the first year, ONTRO's market capitalization is nearly 30 times its current value, and three to five years from now, ONTRO's market capitalization is potentially 110 times its current value. Assumptions: The proceeding estimates of market capitalization do not account for sales of self-heating containers in either Europe or Asia. I have assumed that ONTRO's sales in these markets are more than adequate to cover the future operating expenses of ONTRO. ONTRO's current operating expenses average about $4M per year (see Reference 1). Future increases in operating expenses should be offset by future sales in Europe in Asia. I believe that this is a conservative approach because the future operating expenses of ONTRO are expected to be much less than its future earnings. The number of containers sales (NUMBER) is based on a Business Wire that was dated December 1, 2000 (see Reference 2). In this Business Wire, Consolidated Container Company projected sales of 120 million containers in the first year and 480 million containers in three to five years. Based on this Business Wire, it appears that small market tests will commence in the third quarter of this year. In a later addendum to the Business Wire, James Bernstein, the executive vice-president of ONTRO, indicated that ONTRO's containers will be readily available in the fourth quarter of 2001. These numbers are consistent with an earlier BASES (Booz Allen Sales Estimating System) study that ONTRO provides on its web site (see Reference 3). The BASES study projected first-year sales of 190 million containers. It is worth noting that these sales projections are small compared to the current sales volume of 4 billion containers for Consolidated Container Company (see Reference 4). The price per container (PRICE) is based on an interview of James Scudder, the president of ONTRO, that appeared in the Wall Street Transcript on September 18, 2000 (see Reference 5). In the interview, Mr. Scudder indicates a price range of "... $1.69 and $2.49 depending on the product and the brand cache." The price that I used in the preceding formulas of $2.00 per container is an average sales price. The royalty fee (ROYALTY) is based on a royalty fee that is paid for tamper-evident packaging (see Reference 6). Carter Holt Harvey Limited (http://www.chh.com) charges a 5% royalty for its tamper-evident packaging. I believe that tamper-evident packaging is less complex and less innovative than ONTRO's self-heating container. As a result, the 5% royalty that I used in the preceding formulas is probably conservative. Other evidence that is available on the web indicates that ONTRO's royalty fee could approach 7.5%. The P/E ratio (P/E) is based on the Starbuck's (see Reference 6). The market pays a premium for companies whose main source of income is based on royalty and licensing fees. The current P/E ratio of Starbuck's is about 75. I used a P/E ratio of 40, which is nearly half of Starbuck's. For comparison, the current P/E ratio of McDonalds is about 17. REFERENCES: 1. sec.gov, ONTRO's 10QSB, 11/14/2000. 2. Business Wire, 12/1/2000. Copies of this Business Wire are available on the Yahoo and/or Raging Bull message boards. See messages.yahoo.com and/or ragingbull.lycos.com. 3. See the results of the BASES study at ontro.com under the company and marketing info and the marketing strategy sections. See ontro.com. 4. See the analysis of Consolidated Container Company at hoovers.com. 5. See the Wall Street Transcript Interview at ontro.com under the What's New and Awards/Press Coverage and Links to Published Articles Sections. See ontro.com. 6. See ipresearch.com, Royalty Rates for Technology, 2nd Edition, Intellectual Property Research Associates, 2000. Near the bottom of the web page, the royalty fee is provided for tamper-evident packaging. 7. See quicken.com and quicken.com.